Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumblesfool.comOculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.fool.comThis clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Millionfool.comMineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
